News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nitec Pharma AG's New Rheumatoid Arthritis Treatment, Lodotra, Recommended For European Regulatory Approval


1/12/2009 3:09:55 PM

BASEL/REINACH, Switzerland, January 7 2009 – Nitec Pharma AG (“Nitec” or “Nitec Pharma”), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced that its lead product, Lodotra™, has been recommended for European regulatory approval for the treatment of rheumatoid arthritis (“RA”) and associated morning stiffness. Germany was the Reference Member State and Lodotra™ is now also considered approvable by the regulatory agencies of 14 other countries (the “Euro15”) under the Decentralised Procedure.

Read at PharmaLive


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES